Cardiff Oncology - 53 Year Dividend History | CRDF
Historical dividend payout and yield for Cardiff Oncology (CRDF) since 1971. The current TTM dividend payout for Cardiff Oncology (CRDF) as of December 20, 2024 is $0.00. The current dividend yield for Cardiff Oncology as of December 20, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.230B |
$0.000B |
|
Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
